TY - JOUR AU - Wei, K. R. AU - Zheng, R. S. AU - Zhang, S. W. AU - Liang, Z. H. AU - Ou, Z. X. AU - Chen, W. Q. PY - 2014 DA - 2014// TI - Nasopharyngeal carcinoma incidence and mortality in China in 2010 JO - Chin J Cancer. VL - 33 ID - Wei2014 ER - TY - JOUR AU - Wei, W. I. AU - Sham, J. S. PY - 2005 DA - 2005// TI - Nasopharyngeal carcinoma JO - Lancet. VL - 365 UR - https://doi.org/10.1016/S0140-6736(05)66698-6 DO - 10.1016/S0140-6736(05)66698-6 ID - Wei2005 ER - TY - JOUR AU - Zhang, L. F. AU - Li, Y. H. AU - Xie, S. H. AU - Ling, W. AU - Chen, S. H. AU - Liu, Q. PY - 2015 DA - 2015// TI - Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui County, Guangdong Province, South China: an age-period-cohort analysis JO - Chin J Cancer. VL - 34 ID - Zhang2015 ER - TY - JOUR AU - Wee, J. T. AU - Ha, T. C. AU - Loong, S. L. AU - Qian, C. N. PY - 2010 DA - 2010// TI - Is nasopharyngeal cancer really a "Cantonese cancer"? JO - Chin J Cancer. VL - 29 UR - https://doi.org/10.5732/cjc.009.10329 DO - 10.5732/cjc.009.10329 ID - Wee2010 ER - TY - JOUR AU - Lee, N. AU - Harris, J. AU - Garden, A. S. AU - Straube, W. AU - Glisson, B. AU - Xia, P. PY - 2009 DA - 2009// TI - Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225 JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.19.9109 DO - 10.1200/JCO.2008.19.9109 ID - Lee2009 ER - TY - JOUR AU - Ma, B. B. AU - Poon, T. C. AU - Zee, B. AU - Mo, F. K. AU - Chan, C. M. PY - 2003 DA - 2003// TI - Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study JO - Head Neck VL - 25 UR - https://doi.org/10.1002/hed.10307 DO - 10.1002/hed.10307 ID - Ma2003 ER - TY - JOUR AU - Modjtahedi, H. AU - Essapen, S. PY - 2009 DA - 2009// TI - Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities JO - Anti-Cancer Drugs VL - 20 UR - https://doi.org/10.1097/CAD.0b013e3283330590 DO - 10.1097/CAD.0b013e3283330590 ID - Modjtahedi2009 ER - TY - JOUR AU - Zhang, Z. C. AU - Fu, S. AU - Wang, F. AU - Wang, H. Y. AU - Zeng, Y. X. AU - Shao, J. Y. PY - 2014 DA - 2014// TI - Oncogene mutational profile in nasopharyngeal carcinoma JO - Onco Targets Ther VL - 7 ID - Zhang2014 ER - TY - JOUR AU - Zhang, P. AU - Wu, S. K. AU - Wang, Y. AU - Fan, Z. X. AU - Li, C. R. AU - Feng, M. PY - 2015 DA - 2015// TI - p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: a retrospective study JO - Oncol Lett VL - 9 UR - https://doi.org/10.3892/ol.2014.2631 DO - 10.3892/ol.2014.2631 ID - Zhang2015 ER - TY - JOUR AU - Campbell, N. P. AU - Hensing, T. A. AU - Bhayani, M. K. AU - Shaikh, A. Y. AU - Brockstein, B. E. PY - 2016 DA - 2016// TI - Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck JO - Expert Rev Anticancer Ther VL - 16 UR - https://doi.org/10.1080/14737140.2016.1202116 DO - 10.1080/14737140.2016.1202116 ID - Campbell2016 ER - TY - JOUR AU - Talavera, A. AU - Friemann, R. AU - Gomez-Puerta, S. AU - Martinez-Fleites, C. AU - Garrido, G. AU - Rabasa, A. PY - 2009 DA - 2009// TI - Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-4518 DO - 10.1158/0008-5472.CAN-08-4518 ID - Talavera2009 ER - TY - JOUR AU - Si, X. AU - Wu, S. AU - Wang, H. AU - Zhang, X. AU - Wang, M. AU - Zeng, X. PY - 2018 DA - 2018// TI - Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma JO - Thorac Cancer VL - 9 UR - https://doi.org/10.1111/1759-7714.12789 DO - 10.1111/1759-7714.12789 ID - Si2018 ER - TY - JOUR AU - Garrido, G. AU - Tikhomirov, I. A. AU - Rabasa, A. AU - Yang, E. AU - Gracia, E. AU - Iznaga, N. PY - 2011 DA - 2011// TI - Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile JO - Cancer Biol Ther VL - 11 UR - https://doi.org/10.4161/cbt.11.4.14097 DO - 10.4161/cbt.11.4.14097 ID - Garrido2011 ER - TY - JOUR AU - Liu, Z. G. AU - Zhao, Y. AU - Tang, J. AU - Zhou, Y. J. AU - Yang, W. J. AU - Qiu, Y. F. PY - 2016 DA - 2016// TI - Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis JO - Oncotarget. VL - 7 ID - Liu2016 ER - TY - JOUR AU - You, R. AU - Hua, Y. J. AU - Liu, Y. P. AU - Yang, Q. AU - Zhang, Y. N. AU - Li, J. B. PY - 2017 DA - 2017// TI - Concurrent Chemoradiotherapy with or without anti-EGFR-targeted treatment for stage II-IVb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up JO - Theranostics. VL - 7 UR - https://doi.org/10.7150/thno.19710 DO - 10.7150/thno.19710 ID - You2017 ER - TY - JOUR AU - Cox, J. D. AU - Stetz, J. AU - Pajak, T. F. PY - 1995 DA - 1995// TI - Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) JO - Int J Radiat Oncol Biol Phys VL - 31 UR - https://doi.org/10.1016/0360-3016(95)00060-C DO - 10.1016/0360-3016(95)00060-C ID - Cox1995 ER - TY - JOUR AU - Ng, W. T. AU - Lee, M. C. AU - Hung, W. M. AU - Choi, C. W. AU - Lee, K. C. AU - Chan, O. S. PY - 2011 DA - 2011// TI - Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma JO - Int J Radiat Oncol Biol Phys VL - 79 UR - https://doi.org/10.1016/j.ijrobp.2009.11.024 DO - 10.1016/j.ijrobp.2009.11.024 ID - Ng2011 ER - TY - JOUR AU - Hua, Y. J. AU - Han, F. AU - Lu, L. X. AU - Mai, H. Q. AU - Guo, X. AU - Hong, M. H. PY - 2012 DA - 2012// TI - Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy JO - Eur J Cancer VL - 48 UR - https://doi.org/10.1016/j.ejca.2012.06.016 DO - 10.1016/j.ejca.2012.06.016 ID - Hua2012 ER - TY - JOUR AU - Wang, W. AU - Feng, M. AU - Fan, Z. AU - Li, J. AU - Lang, J. PY - 2014 DA - 2014// TI - Clinical outcomes and prognostic factors of 695 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy JO - Biomed Res Int VL - 2014 ID - Wang2014 ER - TY - JOUR AU - Setton, J. AU - Han, J. AU - Kannarunimit, D. AU - Wuu, Y. R. AU - Rosenberg, S. A. AU - DeSelm, C. PY - 2016 DA - 2016// TI - Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma JO - Oral Oncol VL - 53 UR - https://doi.org/10.1016/j.oraloncology.2015.11.015 DO - 10.1016/j.oraloncology.2015.11.015 ID - Setton2016 ER - TY - JOUR AU - Zhang, M. X. AU - Li, J. AU - Shen, G. P. AU - Zou, X. AU - Xu, J. J. AU - Jiang, R. PY - 2015 DA - 2015// TI - Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up JO - Eur J Cancer VL - 51 UR - https://doi.org/10.1016/j.ejca.2015.08.006 DO - 10.1016/j.ejca.2015.08.006 ID - Zhang2015 ER - TY - JOUR AU - Zhang, J. W. AU - Qin, T. AU - Hong, S. D. AU - Zhang, J. AU - Fang, W. F. AU - Zhao, Y. Y. PY - 2015 DA - 2015// TI - Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma JO - Chin J Cancer VL - 34 ID - Zhang2015 ER - TY - JOUR AU - Li, H. M. AU - Li, P. AU - Qian, Y. J. AU - Wu, X. AU - Xie, L. AU - Wang, F. PY - 2016 DA - 2016// TI - A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma JO - BMC Cancer VL - 16 UR - https://doi.org/10.1186/s12885-016-2974-x DO - 10.1186/s12885-016-2974-x ID - Li2016 ER - TY - JOUR AU - Crombet-Ramos, T. AU - Rak, J. AU - Perez, R. AU - Viloria-Petit, A. PY - 2002 DA - 2002// TI - Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody JO - Int J Cancer VL - 101 UR - https://doi.org/10.1002/ijc.10647 DO - 10.1002/ijc.10647 ID - Crombet-Ramos2002 ER - TY - JOUR AU - Crombet, T. AU - Osorio, M. AU - Cruz, T. AU - Roca, C. AU - Castillo, R. AU - Mon, R. PY - 2004 DA - 2004// TI - Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.03.089 DO - 10.1200/JCO.2004.03.089 ID - Crombet2004 ER - TY - JOUR AU - Ramakrishnan, M. S. AU - Eswaraiah, A. AU - Crombet, T. AU - Piedra, P. AU - Saurez, G. AU - Iyer, H. PY - 2009 DA - 2009// TI - Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin JO - MAbs. VL - 1 UR - https://doi.org/10.4161/mabs.1.1.7509 DO - 10.4161/mabs.1.1.7509 ID - Ramakrishnan2009 ER - TY - JOUR AU - Mao, Y. P. AU - Tang, L. L. AU - Chen, L. AU - Sun, Y. AU - Qi, Z. Y. AU - Zhou, G. Q. PY - 2016 DA - 2016// TI - Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy JO - Chin J Cancer. VL - 35 UR - https://doi.org/10.1186/s40880-016-0167-2 DO - 10.1186/s40880-016-0167-2 ID - Mao2016 ER - TY - JOUR AU - Qu, Y. AU - Chen, Y. AU - Yu, H. AU - Zhao, Y. AU - Chen, G. AU - Bai, L. PY - 2015 DA - 2015// TI - Survival and prognostic analysis of primary nasopharyngeal carcinoma in North China JO - Clin Lab VL - 61 ID - Qu2015 ER - TY - STD TI - Yao JJ, Zhang LL, Gao TS, Peng YL, Lawrence WR, Zhang WJ, et al. Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer Biol Ther. 2018:1–6. ID - ref29 ER -